Search Videos and More
Document
Treatment Guideline: First-Line Treatment of HER2-Positive Metastatic Breast Cancer
The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment of patients with HER2-positive metastatic breast cancer.
News
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026
Results suggest that introducing tarlatamab, a bispecific T-cell engager, earlier in treatment could meaningfully extend survival for a broader group of patients
News
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death
New analysis provides additional evidence on how the PROTEUS regimen compares with standard of care.
News
Dana-Farber presents phase 3 lung cancer data in ESMO presidential symposium
Additional key study updates in prostate, breast and kidney cancer, and a special symposium focused on personalized cancer vaccines
News
Dana-Farber Research News 10.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 - 30.
Symposium
ESMO Congress 2026
Preview news releases and presentations by Dana-Farber Physician-Scientists at this year's ESMO Congress 2026 in Madrid, Spain, October 23 - 27, 2026.
Document
Treatment Guideline: Elinzanetant in Patients with a Breast Cancer and Vasomotor Symptoms
The Breast Oncology Center held meetings to discuss recommendations regarding the use of elinzanetant in patients with a history of breast cancer and vasomotor symptoms.
News
Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.
News
Dana-Farber Research News 10.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 - 15.
Course
Cannabis and Oncology Care: How to Guide Adults with Cancer
Learn evidence-based cannabis therapeutics for oncology patients — including clinical indications, risk assessment, and conversation frameworks-grounded in ASCO's 2024 clinical guideline for adults with cancer.
News
Dana-Farber Researchers Find Blood Test Could Guide Future Treatment in Ewing Sarcoma
Prospective national study validates circulating tumor DNA as a predictor of relapse risk and identifies low-, intermediate-, and high-risk patient groups
Podcast
Season 3, Episode 1: Advances in Endometrial Cancer Research
Cigall Kadoch had a hunch that the research in her lab might be relevant to endometrial cancer research. She had spent more than a decade studying the molecular machinery that unwinds DNA in the nucleus of a cell to make the right DNA instructions readable by the cell at the right time.